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Background: Determination of the tumor marker concentration in peritoneal fluid (PF) may help to assess its
potential to detect small concentration changes between benign ovarian pathology and early stage ovarian cancer.
Peritoneal washing, which can also be obtained when PF is absent, is already included in the International
Federation of Gynecology and Obstetrics (FIGO) staging classification for ovarian cancer but sampling has not yet
been standardized. Since our aim was to evaluate the relationship between marker concentration in PF and
washing, standardization of the sampling protocol was a prerequisite to ensure reliable results.
Methods: Thirty-three women with non-malignant pathology of the reproductive organs were included in the
study. We used three promising tumor markers for evaluation of the marker concentration in local fluid: osteopontin
(sOPN), splice variant 6 of sCD44 (sCD44-v6) and vascular cell adhesion molecule-1 (sVCAM-1). After aspiration of PF,
washing of the uterus, ovaries and pelvic peritoneum was performed with saline solution. Patients were divided into
two groups based on the solution volume: A-20 ml and B-50 ml. To determine the efficiency of washing in relation
to solution volume, washing was repeated three times. Concentrations of markers in samples were determined
using flow cytometry.
Results: Mean concentrations of markers were significantly higher (P <0.001) in PF than in the first washing. We
demonstrated a significant positive correlation between marker concentrations in PF and first washing (sOPN:
r = 0.447, P = 0.048; sCD44-v6: r = 0.660, P = 0.002; sVCAM-1: r = 0.526, P = 0.017). When using a smaller solution
volume for washing, significantly higher (sVCAM-1: 2.5-fold, P = 0.021; sOPN: 3-fold, P = 0.024) or equal (sCD44-v6)
mean concentrations of tumor markers were obtained.
Conclusions: Our work demonstrates for the first time that concentrations of sOPN, sCD44-v6 and sVCAM-1 in PF
correlate with peritoneal washing in women with non-malignant pathology of the reproductive organs. This
indicates that, for selected tumor markers, washing can replace PF when PF is absent. A standardized protocol for
sampling PF and performing washing during laparoscopy was established.
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Ovarian cancer usually presents in advanced stages, with
a high mortality, but has a favorable prognosis if diag-
nosed at an early stage [1,2]. The most clinically useful
ovarian cancer blood tumor markers, cancer antigen 125
(CA125) and human epididymis protein 4 (HE4), are far
from ideal for early detection of the disease due to the
unacceptable level of specificity and sensitivity [2]. One
of the challenges in this field is therefore to identify
tumor markers for the detection of early-stage disease.
However, it is questionable when the number of neo-
plastic cells is low, whether sufficient tumor product can
reach the peripheral blood (a range of 0.1 to 20% of se-
creted protein is assumed) for early disease detection
with diagnostic tests, taking into account the sensitivity
of the blood assay [3]. We can therefore apply a different
approach and evaluate the concentrations of ovarian
cancer markers in the fluid of the local environment.
This approach could help to elucidate the potential of
new blood tumor markers for early-stage disease since
changes in levels of tumor markers in local fluid, due to
higher quantities, are more quickly detectable and are
also more specific [4].
In addition to its use in tumor marker research, this
approach has potential clinical applicability in patients
with suspected adnexal masses, where determination of
tumor markers not only in blood but also in local fluid,
in combination with cytology, may be useful in order to
distinguish more accurately between benign and malig-
nant forms of ovarian neoplasm. However, to set a cut-
off value for local fluid between benign and malignant
disease, control values of tumor markers in women with
benign pathology of the reproductive organs should first
be determined.
In order to obtain control values of markers in local
fluid, a sample of peritoneal fluid (PF) and/or peritoneal
washing can be used, which is already incorporated in
the International Federation of Gynecology and Obstet-
rics (FIGO) staging classification for ovarian cancer [5,6]
although the procedure has not yet been standardized.
In early ovarian cancer, elevation of the concentration of
tumor markers in the local environment may contribute
to surgical staging, especially in cases in which PF is ab-
sent and a representative cytological sample is difficult
to obtain [7-9]. Since peritoneal washing is used in such
cases, knowing the relationship of tumor marker con-
centrations between PF and peritoneal washing is essen-
tial. However, a standard sampling protocol (SSP) is a
prerequisite to ensure reliable results.
For a SSP, tumor markers are needed whose soluble
forms are present in measurable concentrations in
the PF of women with benign pathology of the repro-
ductive organs. Osteopontin (sOPN), a splice variant
6 of CD44 (sCD44-v6) and vascular cell adhesionmolecule-1 (sVCAM-1) were shown in our preliminary
study [10] to be present in determinable concentrations
in PF. In addition, all three are promising tumor markers
present in ovarian cancer cells and/or mesothelial cells.
They are involved in cell motility, adhesion and spreading
free tumor cells through the peritoneal cavity [11-14].
Concentrations in samples, PF and/or peritoneal washing
can be further compared to their serum concentrations,
thereby offering many research and clinical applications
if the correlation can be proved. As already demon-
strated in advanced ovarian cancer patients, the results
of sVCAM-1 concentrations in serum and ascites have
shown a strong correlation, indicating that the serum
values of sVCAM are the result of concentration changes
in the local environment [14].
In present study we focused only on the proportion of
concentrations of ovarian cancer tumor markers in PF
and peritoneal washing using SSP, in order to elucidate
whether washing could replace PF. SSP was performed
in a group of patients with benign pathology of the re-
productive organs using sOPN, sCD44-v6 and sVCAM-
1. In particular, we tried to elucidate the influence of the
solution volume used for performing washing on tumor
marker concentrations in washing samples and on the
efficacy of the washing procedure.
Methods
Patients
The study included 33 patients with benign pathology of
the reproductive organs who were operated reject at the
Department of Gynecology, University Medical Centre
Ljubljana between December 2011 and September 2013.
Exclusion criteria were gynecological malignancies, ele-
vated parameters of inflammation (C-reactive protein
and total white blood cell count), hysteroscopy and ele-
vated standard tumor markers (Ca125, Ca15-3, Ca19-9
and CEA). Patients were in the reproductive (during
follicular or luteal phases), perimenopausal or postmen-
opausal phase. Family, general, gynecological and obstet-
ric history, indication for surgery, other relevant diseases
and current therapy were collected from medical re-
cords. The purpose of the SSP was explained to all pa-
tients and written informed consent was obtained prior
to enrolment. The study was approved by the Commis-
sion of the Republic of Slovenia for Medical Ethics (ap-
proval number: 82/01711) and in accordance with the
Declaration of Helsinki.
Protocol for aspirating peritoneal fluid and performing
peritoneal washing during laparoscopy
During the procedure, patients underwent standard lapar-
oscopy. No solution was injected before inflation that
could alter the volume of PF. The SSP was not performed
in the case of adhesions that would prevent its optimal
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cavity, all the available PF was aspirated from the cavum
Douglasi through the cannula into a syringe. This was
followed by the washing procedure. If PF was not
present, the washing procedure was performed directly
after entering the abdominal cavity. Washing was per-
formed by spilling 0.9% NaCl solution onto the surface
of the uterus, ovaries and pelvic peritoneum. The solu-
tion was left for 2 minutes in the pelvic cavity. The total
volume (in an ideal anatomical condition) was aspirated
back into the syringe for calculating the absolute quan-
tity of tumor markers.
Based on the solution volume for washing, patients
were divided into two groups: group A (smaller volume)
and group B (larger volume). We took care to include
patients with various diagnoses in each group. Because
the procedure was time-demanding, washing was ini-
tially performed on only seven patients in each group
and their samples were analyzed in order to choose
which volume was better for final standardization of the
washing procedure on a larger number of patients. First
washing in group A and group B was performed with 20
and 50 ml, respectively. To determine the efficiency of
washing in relation to the solution volume, the proced-
ure was repeated twice after the first washing; in group
A by using 20 ml and 10 ml of solution and in group B by
using 50 ml and 20 ml of solution. The last washing was
performed with a smaller volume to avoid the concentra-
tion of tumor markers falling below the detection limit for
the analytical method. After comparison of tumor marker
concentrations between the two groups, we selected the
smaller volume and included an additional 19 patients.
Since the emphasis of our analysis was on the first wash-
ing, which is clinically useful, we performed it on all add-
itional 19 patients (altogether on 26 patients); the second
and third washings were performed on 13 additional pa-
tients (altogether on 20 patients).
Samples of PT and washings were immediately trans-
ferred into a conical tube, which was kept on ice until cen-
trifugation at 1000 × g for 10 minutes at 4°C within
30 minutes. The volume of each PF and washing sample
was recorded before centrifugation. Samples contaminated
with blood were excluded from the analysis. Supernatants
were stored in aliquots at -80°C. No more than two
freeze-thaw cycles were allowed for any sample.
Analysis of sOPN, sCD44-v6 and sVCAM-1 with bead-based
flow cytometric assay
Concentrations of sOPN, sCD44-v6 and sVCAM-1 in
samples were measured separately using a FlowCytomix
Simplex Kit (eBioscience, Vienna, Austria). The kit
consists of fluorescent microspheres with an emission
wavelength at 700 nm (5 μm diameter for sOPN and
sCD44-v6 analysis and 4 μm diameter for sVCAM-1analysis). Microspheres are coated with specific antibodies
raised against each of the analytes (sOPN, sCD44-v6
or sVCAM-1). They also contain a biotin-conjugated sec-
ond antibody and streptavidin-phycoerythrin emitting at
575 nm. Samples were run on a Cell Lab Quanta™ SC-
MPL (Beckman Coulter, Fullerton, United States). Elec-
tronic volume versus side scatter gating was employed to
exclude any sample particles other than 5 μm (4 μm) mi-
crospheres. Samples were acquired by Cell Lab QuantaTM
SC-MPL software (Beckman Coulter, Fullerton, United
States) and analyzed using Flowcytomix™ Pro 3.0 software
(eBioscience, Vienna, Austria). The lower limits of detec-
tion of sOPN, sCD44-v6 and sVCAM-1 were 0.432 ng/ml,
0.126 ng/ml and 0.9 ng/ml, respectively.
Statistical analysis
To determine the efficiency of washing in relation to the
volume of solution for performing the procedure, we cal-
culated the absolute quantity of sOPN, sCD44-v6 and
sVCAM-1 separately in three consecutively performed
washings. In the calculation, the tumor marker concen-
tration (ng/ml) in each sample of washing was multiplied
by the volume of aspired washing (ml). We summed the
absolute quantities of tumor marker in all three consecu-
tively performed washings to determine the percentage of
each tumor marker acquired from the first washing. All
data are presented as mean ± standard error of mean
(SEM). Pearson’s correlation coefficient was used to calcu-
late the strength of the relationship between normally dis-
tributed variables. Data were compared by the Student’s
unpaired t-test. A P value of <0.05 was considered signifi-
cant. Statistical analysis was performed using software
statistical package SPSS, version 19 (IBM Statistics, New
York United States).
Results
The characteristics of the investigated 33 aprove patients
are summarized in Table 1.
The influence of solution volume used for washing on
sOPN, sCD44-v6 and sVCAM-1 concentrations in the
washing samples and on the efficiency of the washing
procedure
Based on the volume of solution used for washing, the
patients were divided into two groups: group A (smaller
volume) and group B (larger volume). The emphasis of
our analysis was on the first washing, which can be used
as a substitute for PF if PF is not present. In the first
washing of patients in group A, the mean sVCAM-1
concentration was 2.5-fold higher (P = 0.021) and sOPN
3-fold higher (P = 0.024) than the mean concentration in
the first washing of patients in group B. However, there
was no effect of solution volume on mean sCD44-v6
concentration in the first washing (Table 2). In both
Table 1 Patient characteristics
Parameters
Number of patients 33
age (average ± SEM) 43 ± 1.82 years
range 21-69 years
Diagnosis, number of patients (%)
benign ovarian cyst 8 (24%)
myoma of the uterus 16 (48%)
pelvic pain, sterilization 7 (24%)
preventive adnexectomy 2 (6%)




Phase of menstrual cycle, number of patients (%)
luteal 10 (30%)
follicular 7 (21%)
not applicable 16 (48%)
Free peritoneal fluid
present, number of patients (%) 26 (79%)
absent, number of patients (%) 7 (21%)
volume (mean ± SEM) 6.03 ± 1.22 ml
Contraception, number of patients (%)
intrauterine device 4 (12%)
combined hormone therapy 3 (9%)
Table 2 Concentrations of sOPN, sCD44-v6 and sVCAM-1
(average ± SEM) in peritoneal fluid and in washings
performed with 0.9% NaCl solution
Sample (number of patients) sOPN sCD44-v6 sVCAM-1
(ng/ml)
Groups A + B (33)
Peritoneal fluid (26) 132.1 ± 22.9 45.3 ± 3.4 438.8 ± 11.7
range 21.4 - 483.1 19.3 - 89.3 311.8 - 588.43
Group A (smaller volume of solution for performing washing)
Washing 1A (26) 20.0 ± 6.5 4.6 ± 0.5 108.2 ± 14.7
Washing 2A (20) 7.2 ± 2.7 2.3 ± 0.4 34.4 ± 6.7
Washing 3A (20) 6.0 ± 3.0 1.8 ± 0.4 28.3 ± 6.7
Group B (larger volume of solution for performing washing)
Washing 1B (7) 6.7 ± 1.7 5.5 ± 1.3 46.2 ± 11.6
Washing 2B (7) 3.0 ± 1.8 2.6 ± 0.9 20.7 ± 6.7
Washing 3B (7) 2.2 ± 0.5 2.1 ± 1.0 22.1 ± 8.5
Concentration ratio
Peritoneal fluid : washing 1A 6.6 9.8 4.1
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sVCAM-1 in three consecutively performed washings de-
creased, except the sVCAM-1 concentration between the
second and third washings in group B (Table 2). A signifi-
cant positive correlation between the first and second
washings was observed for sOPN (r = 0.951, P <0.001),
sCD44-v6 (r = 0.884, P <0.001) and sVCAM-1 (r = 0.813,
P = 0.003), as well as between the second and third wash-
ings for sOPN (r = 0.985, P <0.001), sCD44-v6 (r = 0.991,
P <0.001) and sVCAM-1 (r = 0.961, P <0.001) (Figure 1).
Three washings were performed consecutively in pa-
tients of group A with a smaller volume of solution (1A:
20 ml, 2A: 20ml and 3A: 10 ml) and in patients of group
B with a larger volume of solution (1B: 50 ml, 2B: 50 ml
and 3B: 20 ml).
In order to elucidate the influence of volume size on
the efficiency of the washing procedure, we calculated
the absolute quantity of sOPN, sCD44-v6 and sVCAM-1
in three consecutively performed washings. For this pur-
pose, we measured the volumes of aspirated washings.
In group A, the mean aspirated volume of the first, sec-
ond and third washings were 15 ml, 16 ml and 9 ml and
in group B were 43 ml, 42 ml and 19 ml, respectively.
The proportions of aspirated washing solution based on
the solution volume used for washing were 73%, 82%
and 90% in group A and 85%, 85% and 95% in group B.
The mean absolute quantity of sOPN and sVCAM-1 in
all three washings of patients in group A did not signifi-
cantly differ from that in group B. In contrast, the mean
absolute quantity of sCD44-v6 of all three washings
of patients was significantly higher in group B than
in group A; first washing: P <0.001, second washing:
P = 0.002 and third washing: P = 0.036 (Figure 2). In
three consecutively performed washings, the mean abso-
lute quantity of sOPN, sCD44-v6 and sVCAM-1 de-
creased in patients of both groups. In the second and
third washings of both groups, the mean concentrations
of sOPN, sCD44-v6 and sVCAM-1 were significantly
lower than in the first washing (Figure 2). With the first
washing, we acquired 61 to 65% of the total quantity of
each tumor biomarker in the three consecutively per-
formed washings, regardless of solution volume.
Concentrations of sOPN, sCD44-v6 in sVCAM-1 in peritoneal
fluid and the first washing of patients in group A
Mean concentrations of tumor markers in PF (sOPN:
144.42 ± 29.07 ng/ml, sCD44-v6: 39.20 ± 2.37 ng/ml and
sVCAM-1: 441.78 ± 20.79 ng/ml) were significantly higher
(P <0.001) than in the first washing (sOPN: 19.98 ±
6.57 ng/ml, sCD44-v6: 4.56 ± 0.56 ng/ml and sVCAM-1:
108.21 ± 14.75 ng/ml) (Table 2). To elucidate whether
the first washing might replace PF if PF is not present,
we evaluated the association of tumor marker concentra-















































































Figure 1 Correlation of sOPN, sCD44-v6 and sVCAM-1 concentrations between first and second washings, as well as between second
and third washings. Three washings were performed consecutively in patients of group A with 20 ml, 20 ml and 10 ml of 0.9% NaCl solution.
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concentrations of sOPN (r = 0.447, P = 0.048), sCD44-v6
(r = 0.660, P = 0.002) and sVCAM-1 (r = 0.526, P = 0.017)
in PF and the first washing (Figure 3).
Clinical characteristics of the investigated patients in relation
to the concentration of sOPN, sCD44-v6 and VCAM-1
Concentrations of sOPN, sCD44-v6 and sVCAM-1 in PF
or washing samples were not associated with the pres-
ence of benign ovarian cysts, phase of menstrual cycle
or contraception. The mean volume of PF was 7.66 ±
1.38 ml (group A: 7.26 ± 1.54 ml; group B: 8.98 ± 3.3 ml).
PF was present in 26 (79%) patients. However, the pres-
ence of PF was not associated with a higher concentra-
tion of tumor markers in the first washing.
Discussion
Extensive research in the field of serum tumor markers
for early detection of ovarian cancer is currently under-
way, with many promising candidates, although none of
them have as yet fulfilled expectations [15,16]. The aim
of this study was to apply a different approach and
evaluate the control concentrations of ovarian cancer
markers in local fluid of patients with benign pathologyof the reproductive organs. This approach could help
to elucidate the potential of promising blood tumor
markers for early-stage disease, since tumor markers
closer to the origin of disease are more specific and their
changes of concentration can be detected faster. We
used PF and/or peritoneal washing to obtain control
values of tumor markers in local fluid, which is already
included in the FIGO staging classification for ovarian
cancer although the protocol of sampling has not so
far been standardized [5,6]. In early stages of ovarian
cancer, when ascites is often not present, PF accumu-
lated in the cavum Douglasi plays a crucial role in dis-
ease progression as a result of dissemination of detached
tumor cells into the peritoneal cavity and adhesion to
mesothelial cells of the peritoneum and other abdominal
organs [17-19].
That SSP is a prerequisite to ensuring reliable results
was also demonstrated by our preliminary results for
sVCAM-1 in patients with a benign pathology of repro-
ductive organs, in which samples were collected without
SSP, with the exception of the instruction to perform
washing with 20 ml of 0.9% NaCl solution. sVCAM-1
has a wide concentration range and concentrations of
sVCAM-1 in some samples were below the detection
Figure 2 Comparison of absolute quantity (ng) of sOPN,
sCD44-v6 and sVCAM-1 among three consecutively performed
washings, as well as between group A (black bars) and group B
(grey bars). In comparison to the first, the absolute quantity of all
three tumor markers significantly decreased in the second and third
washings within both groups. There was no significant difference
in absolute quantity of sOPN and sVCAM-1 between groups A and
B in any of the three washings. However, there was a significant
difference in absolute quantity of sCD44-v6 between groups A and
B in all three washings. Washings were performed consecutively in
patients of group A with a smaller volume of solution (1A: 20 ml,
2A: 20 ml and 3A: 10 ml) and in patients of group B with a larger
volume of solution (1B: 50 ml, 2B: 50 ml and 3B: 20 ml). Tumor
marker absolute quantity was calculated by multiplying tumor
marker concentration (ng/ml) with the volume of aspirated washing
(ml). *P <0.05, **P <0.01, ***P <0.001.
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BK, MJ). In order to elucidate whether the findings of
the present study can be generally applied for tumor
markers and not just for sVCAM-1, we included sOPN
and sCD44-v6 in our study. sOPN and sCD44-v6 were
shown in our preliminary study [10] to be present in de-
terminable concentrations in PF. sOPN and sVCAM-1
are included in the list of top blood tumor markers for
early detection of ovarian cancer [15,16] and sCD44-v6
has been shown to be useful in differential diagnosis of
benign and malignant ascites [13]. Ascites is a patho-
logical increase in the volume of PF present in 27% of
patients with early-stage ovarian cancer and in 50% of
borderline ovarian cancers [8].
Performing washing is a complex procedure involving
many factors, which is why each surgeon must follow
the instructions of the SSP if comparable results among
patients are to be obtained. The current work therefore
standardized the main factors of the sampling procedure:
determination of the solution volume and the time the
solution is left in the pelvic cavity, specification of areas
for washing and accuracy during aspiration of the whole
solution volume (in an ideal anatomical condition) back
into the syringe. The solution volume is the most im-
portant factor in determining the tumor marker concen-
tration. We found very varied data on the volume in
published studies, from 10 to 1000 ml [7,9,20,21]. In
order to elucidate the influence of solution volume on
tumor marker concentrations, we compared the results
acquired with two different volumes (20 in 50 ml), while
the time and areas of washing were always the same.
The mean concentration of sOPN was 3-fold and the
mean concentration of sVCAM-1 was 2.5-fold higher
when washing with a smaller volume was performed,
while the mean concentrations of sCD44-v6 were simi-
lar. These results demonstrate that a smaller volume is
more appropriate for washing, in order to avoid the con-







































Figure 3 Correlation of sOPN, sCD44-v6 and sVCAM-1 concentrations between peritoneal fluid and the first washing in patients of
group A. Washing was performed with 20 ml of 0.9% NaCl solution.
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crease in tumor marker sensitivity. Additionally, the pro-
cedure was technically easier to perform because a
smaller volume of washing sample can be aspirated back
into the syringe faster than a larger one. In contrast to
our preliminary results for sVCAM-1 (unpublished ob-
servations KC, BK, MJ), none of the results when using
SSP were below the detection limit. When we calculated
the absolute quantity of sOPN and sVCAM-1, we found
that the larger volume only diluted the samples. The
amounts of the tumor markers were the same regardless
of volume, so the effectiveness of washing was also the
same. However, the absolute quantity of sCD44-v6 was
higher when washing was performed with the larger vol-
ume. We discovered that, probably due to specific phys-
ical factors, the baseline values of sCD44-v6 in group B
were different from those in group A, since the mean
concentration of sCD44-v6 in the PF of group B patients
was statistically significantly higher than that in group
A, whereas the mean concentrations of sOPN and
sVCAM-1 in PF were not significantly different between
groups. Another explanation might be the different
physiochemical properties of the sCD44-v6 molecule
(such as better solubility in saline solution). A limitation
of our study was that it was impossible to perform the
washing procedure with different volumes on the same
patient. In an attempt to clarify the process of washing
the pelvic cavity, we repeated the same procedure twice
and our results demonstrated that we had fully washed
the tumor markers from the pelvic surface. First, using
the absolute quantity, we demonstrated that the mean
absolute quantity of tumor markers in three consecu-
tively performed washings decreased. Second, when
tumor marker concentrations were compared among
three consecutively performed washings, their concen-
trations were strongly correlated between the first andsecond washings, as well as between the second and
third washings.
PF is an excellent body fluid for determining control
values of tumor markers in the local tumor environ-
ment, although it is known that PF is sometimes not
present in the cavum Douglasi [7,22]. Comparable to
published data, we found PF was absent in 21% of pa-
tients [7]. In such a situation, washing can replace PF as
a control of the local environment. To discover whether
this is possible, concentrations of tumor markers were
determined separately in PF and washing. In patients
with PF present, therefore, we first aspirated all fluid
from the cavum Douglasi and then performed washing.
As mentioned earlier, a smaller volume of solution is ap-
propriate for washing, so we further evaluated only the
results of tumor marker concentrations in washing ob-
tained with the smaller volume. The results of the
present study determined a positive correlation between
PF and washing concentrations of tumor markers, show-
ing that washing can replace PF in a situation in which
PF is absent. The mean concentrations of tumor markers
were significantly higher in PF than in washing; approxi-
mately 7-fold for sOPN, 10-fold for sCD44-v6 and 4-fold
for sVCAM-1. These results demonstrate the import-
ance of ensuring that all PF is first aspirated from the
cavum Douglasi. We evaluated whether higher levels of
tumor markers in washing are associated with the pres-
ence of PF and found that the presence of PF was not
associated with higher concentrations in washing. This
finding also proved that our results of washings were
not affected by inaccurate aspiration of PF. The results
of the sVCAM-1 concentration in PF and washing in
this study showed that the wide range of concentrations
in our preliminary results of sVCAM-1 in washings (un-
published observations KC, BK, MJ) was probably be-
cause of sampling without a standardized protocol.
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was much narrower (10-fold) when using the SSP. A
consequence of the wide concentration range is a large
standard deviation, which affects setting the cut-off
value for the tumor marker [3]. We also determined pre-
liminary control values of sOPN, sCD44-v6 and
sVCAM-1 in PF and washing based on the SSP, although
a follow-up study with a larger number of patients is
needed to determine their final values.
The SSP could also be applied in patients with ovarian
cancer. Peritoneal washing for cytology is already part
of routine practice in ovarian cancer, either during ini-
tial evaluation or second-look procedures as part of the
FIGO staging classification, being of the utmost import-
ance in early-stage disease for detecting early spread of
the disease [5,6]. Since ascites is not present in 83% of
patients with early-stage ovarian cancer and in 50% of
patients with borderline tumors [8], washing provides a
sample of local fluid that can be obtained in such cases.
Among factors that may contribute to the relatively
high false-negative rate (20%) of cytology is infrequent
exfoliation of malignant cells, but washing not being
performed correctly can also be a factor [23,24]. A SSP
can thus make a contribution to cytology sampling,
since an increased level of tumor marker(s) in periton-
eal washing could still be detected [9]. Determination of
tumor marker(s) concentration in washing may thus be
useful in combination with cytology in order to obtain
more accurate results, especially in classification of
early-stage disease.
The next step in our research will be to evaluate the
relationship between local concentrations and those in
serum. According to the results of sVCAM-1 obtained
in advanced cancer patients [14], serum values in be-
nign conditions, as well as in ovarian cancer, should
demonstrate the same ratio of concentrations towards
tumor marker concentrations in the local environment.
To evaluate the potential of a novel tumour marker to
discriminate between benign and malignant disease, its
level in peritoneal washing of patients with benign
pathology of the reproductive organs as well as follow
up study on sufficient number of patients with stage
I ovarian cancer should be conducted where SPSS will
be applied.
Conclusions
This is the first study to demonstrate a positive correl-
ation between concentrations of selected tumor markers
(sOPN, sCD44-v6 and sVCAM-1) in PF and washing in
women with non-malignant pathology of the reproduct-
ive organs, which indicates that for selected tumor
markers, washing can replace PF when PF is absent. The
present study shows that a SSP is necessary to obtain
comparable results among patients. The SSP could alsobe applied in patients with ovarian cancer. We standard-
ized the main factors of the sampling procedure, in par-
ticular the solution volume for performing washing. A
smaller volume of washing solution is preferable to a lar-
ger one because of higher or equal concentrations of
markers in samples, which allow their detection without
loss of efficiency of washing, and the procedure is also
technically easier to perform.
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